{
    "root": "3532764f-32ae-3083-e063-6394a90a111e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sevelamer Carbonate",
    "value": "20250515",
    "ingredients": [
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "DIACETYLATED MONOGLYCERIDES",
            "code": "5Z17386USF"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "MB5IUD6JUA"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "ZINC STEARATE",
            "code": "H92E6QA4FV"
        },
        {
            "name": "SEVELAMER CARBONATE",
            "code": "9YCX42I8IU"
        }
    ],
    "indications": "Sevelamer carbonate tablets are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis.",
    "contraindications": "• Starting dose of sevelamer carbonate tablets is 0.8 or 1.6 grams administered orally three times per day with meals based on serum phosphorus levels for adult patients and based on body surface area (BSA) category for pediatric patients. ( 2.1 ) • Titrate by 0.8 g per meal in two-week intervals for adult patients as needed to obtain serum phosphorus target. ( 2.1 ) • Titrate based on BSA category for pediatric patients in two-week intervals for 6 weeks and then every 4 weeks as needed to obtain serum phosphorus target. ( 2.1 )",
    "warningsAndPrecautions": "Tablets: Sevelamer Carbonate Tablets 800 mg are supplied as white to off white, oval shaped, biconvex, film-coated tablets imprinted with “L 28” on one side and plain on other side.\n                  \n                  NDC: 72162-2499-1: 100 Tablets in a BOTTLE\n                  NDC: 72162-2499-2: 270 Tablets in a BOTTLE\n                  NDC: 72162-2499-4: 50 Tablets in a BOTTLE\n                  NDC: 72162-2499-9: 90 Tablets in a BOTTLE\n                  \n                  Storage: Store at 20° to 25°C (68° to 77°F): excursions permitted to 15° to 30°C (59° to 86°F).\n  \n[See USP controlled room temperature]\n \n                  Protect from moisture. Dispense in a tight container.\n                  \n                  Repackaged/Relabeled by:\n  \nBryant Ranch Prepack, Inc.\n  \nBurbank, CA 91504",
    "adverseReactions": "Sevelamer carbonate tablets are contraindicated in patients with bowel obstruction.\n                  Sevelamer carbonate tablets are contraindicated in patients with known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or to any of the excipients."
}